Hybrid drug combination: Anti-diabetic treatment of type 2 diabetic Wistar rats with combination of ellagic acid and pioglitazone

Phytomedicine

Volumn 37, Issue , 2017, Pages 4-9

  Nankar, Rakesh P ^a   Doble, Mukesh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

Adiponectin; Ellagic acid; Pioglitazone; Synergy; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ELLAGIC ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHOLESTEROL; SLC2A4 PROTEIN, RAT; STREPTOZOCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; INSULIN SIGNALING; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIPID DIET; LIVER FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT; SKELETAL MUSCLE; ANIMAL; BLOOD; BODY WEIGHT; COMBINATION DRUG THERAPY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; LIVER; METABOLISM; WISTAR RAT;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DRUG THERAPY, COMBINATION; ELLAGIC ACID; GLUCOSE TRANSPORTER TYPE 4; HYPOGLYCEMIC AGENTS; LIVER; MALE; PPAR GAMMA; RATS, WISTAR; STREPTOZOCIN; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 85032977765     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2017.10.014     Document Type: Article

References (23)

1. Bagshaw, S.M., Gibney, R.T.N., Conventional markers of kidney function. Crit. Care Med. 36 (2008), S152–S158.
2. Dormandy, J.A., Charbonnel, B., Eckland, D.J.A., Erdmann, E., Massi-Benedetti, M., Moules, I.K., Skene, A.M., Tan, M.H., Lefebvre, P.J., Murray, G.D., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. The Lancet 366 (2005), 1279–1289.
3. Erion, D.M., Kotas, M.E., McGlashon, J., Yonemitsu, S., Hsiao, J.J., Nagai, Y., Iwasaki, T., Murray, S.F., Bhanot, S., Cline, G.W., CREB-regulated transcription coactivator 2 (CRTC2) promotes glucagon clearance and hepatic amino acid catabolism to regulate glucose homeostasis. J. Biol. Chem. 288 (2013), 16167–16176.
4. Fortson, W.C., Tedesco, F.J., Starnes, E.C., Shaw, C.T., Marked elevation of serum transaminase activity associated with extrahepatic biliary tract disease. J. Clin. Gastroenterol. 7 (1985), 502–505.
5. Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., Shaw, J.E., Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 103 (2014), 137–149.
6. Hashmi, A., Pioglitazone suspension and its aftermath: a wake up call for the Indian drug regulatory authorities. J. Pharmacol. Pharmacotherapeutics, 4, 2013, 227.
7. Kerner, W., Bruckel, J., Definition, classification and diagnosis of diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 122 (2014), 384–386.
8. Liu, Y., Palanivel, R., Rai, E., Park, M., Gabor, T.V., Scheid, M.P., Xu, A., Sweeney, G., Adiponectin stimulates autophagy and reduces oxidative stress to enhance insulin sensitivity during high-fat diet feeding in mice. Diabetes 64 (2015), 36–48.
9. Masiello, P., Broca, C., Gross, R., Roye, M., Manteghetti, M.l., Hillaire-Buys, D., Novelli, M., Ribes, G.r., Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 47 (1998), 224–229.
10. Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L.J., DeFronzo, R.A., Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87 (2002), 2784–2791.
11. Mohan, V., Bedi, S., Unnikrishnan, R., Sahay, B.K., Joshpi, S., Misra, A., Pioglitazone-where do we stand in India?. J. Assoc. Physicians India 60 (2012), 68–70.
12. Mohler, M.L., He, Y., Wu, Z., Hwang, D.J., Miller, D.D., Recent and emerging anti-diabetes targets. Med. Res. Rev. 29 (2009), 125–195.
13. Mooradian, A.D., Dyslipidemia in type 2 diabetes mellitus. Nat. Clin. Pract. Endocrinol. Metab. 5 (2009), 150–159.
14. Nagappa, A.N., Thakurdesai, P.A., Rao, N.V., Singh, J., Antidiabetic activity of Terminalia catappa Linn fruits. J. Ethnopharmacol. 88 (2003), 45–50.
15. Nankar, R.P., Doble, M., Ellagic acid potentiates insulin sensitising activity of pioglitazone in L6 myotubes. J. Funct. Foods 15 (2015), 1–10.
16. Nankar, R.P., Doble, M., Ellagic acid restores TBHP-induced reduction in 2-NBDG uptake in L6 myotubes. MedChem-2015, 2015, IIT Madras, Chennai.
17. Phillips, S.A., Ciaraldi, T.P., Oh, D.K., Savu, M.K., Henry, R.R., Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am. J. Physiol. Endocrinol. Metab. 295 (2008), E842–E850.
18. Prabhakar, P.K., Prasad, R., Ali, S., Doble, M., Synergistic interaction of ferulic acid with commercial hypoglycemic drugs in streptozotocin induced diabetic rats. Phytomedicine 20 (2013), 488–494.
19. Roy, S., Metya, S.K., Sannigrahi, S., Rahaman, N., Ahmed, F., Treatment with ferulic acid to rats with streptozotocin-induced diabetes: effects on oxidative stress, pro-inflammatory cytokines, and apoptosis in the pancreatic β cell. Endocrine 44 (2013), 369–379.
20. Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C.L., Ramarao, P., Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52 (2005), 313–320.
21. Szkudelski, T., The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 50 (2001), 537–546.
22. Tomlinson, J.W., Sinha, B., Bujalska, I., Hewison, M., Stewart, P.M., Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J. Clin. Endocrinol. Metab. 87 (2002), 5630–5635.
23. Yin, H., Park, S.-Y., Wang, X.-J., Misawa, R., Grossman, E.J., Tao, J., Zhong, R., Witkowski, P., Bell, G.I., Chong, A.S., Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin. PloS One, 8, 2013, e65777.